243 filings
Page 2 of 13
UPLOAD
b5fc7hkdodn7sxwnplyi
10 Nov 23
Letter from SEC
12:00am
CORRESP
cz691mt0oyl e4
9 Nov 23
Correspondence with SEC
12:00am
8-K
0sy467 dyzb5fmgm3i1
2 Nov 23
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
2:56pm
8-K
creeoul175wp4
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
DEFA14A
0k4 7yl00
27 Oct 23
Additional proxy soliciting materials
4:08pm
8-K
599hxfa
24 Oct 23
Regulation FD Disclosure
4:18pm
8-K
h4tpmc0tsivbokvfal
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
NT 10-K
ute dx47u
29 Sep 23
Notice of late annual filing
11:30am
8-K
ey67fq825eeuz1e p5
25 Sep 23
Other Events
4:12pm
8-K
wjl6uez6fi97p
22 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:29pm
8-K
2u8h4l
7 Sep 23
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
6:35pm
8-K
xsvyzkm5p7 xazxyn
24 Jul 23
Regulation FD Disclosure
4:26pm
8-K
tq9mqq4zwxvu2 c8i
20 Jul 23
Regulation FD Disclosure
2:18pm
8-K
qxk19ujzg7s2e9l
22 Jun 23
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
4:28pm
8-K
fvw b3d5uwmo4jc7
1 Jun 23
InMed’s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting
1:27pm
8-K
oguvfd3s l3hwet82lu
25 May 23
Regulation FD Disclosure
12:35pm
8-K
3jbv7cvnd42f76j9em
19 May 23
Regulation FD Disclosure
1:41pm